Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Conditions
- Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06974786
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06773910
- Locations
- 🇺🇸
Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05972135
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
- Conditions
- Non-small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT05948462
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Messino Cancer Center, Asheville, North Carolina, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05748834
- Locations
- 🇺🇸
Alliance Cancer Specialists, Bensalem, Pennsylvania, United States
🇺🇸Maryland Oncology Hematology, Columbia, Maryland, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 121
- Registration Number
- NCT04699630
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT04402138
- Locations
- 🇺🇸
Tulane University, Office of Clinical Research, New Orleans, Louisiana, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸HCA Midwest, Kansas City, Missouri, United States
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, AcuteMyelodysplastic Syndrome Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT04361058
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04209725
- Locations
- 🇺🇸
HCA Midwest, Kansas City, Missouri, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT04200365
- Locations
- 🇺🇸
Texas Oncology - Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Transplant Institute, San Antonio, Texas, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States